SE0103839D0 - Pharmaceutical formulation & product - Google Patents

Pharmaceutical formulation & product

Info

Publication number
SE0103839D0
SE0103839D0 SE0103839A SE0103839A SE0103839D0 SE 0103839 D0 SE0103839 D0 SE 0103839D0 SE 0103839 A SE0103839 A SE 0103839A SE 0103839 A SE0103839 A SE 0103839A SE 0103839 D0 SE0103839 D0 SE 0103839D0
Authority
SE
Sweden
Prior art keywords
alpha
product
drug
patient
methylpropiono
Prior art date
Application number
SE0103839A
Other languages
English (en)
Swedish (sv)
Inventor
Nicola Bateman
Julie Cahill
Neill Carman
Ian Cockshott
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Priority to SE0103839A priority Critical patent/SE0103839D0/xx
Publication of SE0103839D0 publication Critical patent/SE0103839D0/xx
Priority to TW091132270A priority patent/TW200406200A/zh
Priority to UY27539A priority patent/UY27539A1/es
Priority to IL16190202A priority patent/IL161902A0/xx
Priority to ARP020104386A priority patent/AR037390A1/es
Priority to EP02779684A priority patent/EP1448168B1/de
Priority to US10/495,012 priority patent/US20050038111A1/en
Priority to PCT/GB2002/005159 priority patent/WO2003043606A1/en
Priority to ES02779684T priority patent/ES2278063T3/es
Priority to KR1020047007359A priority patent/KR20050044468A/ko
Priority to DE60217390T priority patent/DE60217390T2/de
Priority to CNA028272277A priority patent/CN1615122A/zh
Priority to AT02779684T priority patent/ATE350016T1/de
Priority to MXPA04004591A priority patent/MXPA04004591A/es
Priority to AU2002343024A priority patent/AU2002343024A1/en
Priority to JP2003545287A priority patent/JP2005514355A/ja
Priority to BR0214135-3A priority patent/BR0214135A/pt
Priority to CA002466986A priority patent/CA2466986A1/en
Priority to ZA200403689A priority patent/ZA200403689B/en
Priority to NO20042502A priority patent/NO20042502L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Inorganic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SE0103839A 2001-11-16 2001-11-16 Pharmaceutical formulation & product SE0103839D0 (sv)

Priority Applications (20)

Application Number Priority Date Filing Date Title
SE0103839A SE0103839D0 (sv) 2001-11-16 2001-11-16 Pharmaceutical formulation & product
TW091132270A TW200406200A (en) 2001-11-16 2002-10-31 Pharmaceutical formulation
UY27539A UY27539A1 (es) 2001-11-16 2002-11-13 Formulación farmacéutica
CA002466986A CA2466986A1 (en) 2001-11-16 2002-11-14 Pharmaceutical formulation comprising bicalutamide
ES02779684T ES2278063T3 (es) 2001-11-16 2002-11-14 Formulacion farmaceutica que comprende bicalutamida.
AT02779684T ATE350016T1 (de) 2001-11-16 2002-11-14 Bicalutamid enthaltende pharmazeutische zusammensetzung
EP02779684A EP1448168B1 (de) 2001-11-16 2002-11-14 Bicalutamid enthaltende pharmazeutische zusammensetzung
US10/495,012 US20050038111A1 (en) 2001-11-16 2002-11-14 Pharmaceutical formulation comprising bicalutamide
PCT/GB2002/005159 WO2003043606A1 (en) 2001-11-16 2002-11-14 Pharmaceutical formulation comprising bicalutamide
IL16190202A IL161902A0 (en) 2001-11-16 2002-11-14 Pharmaceutical formulation comprising bicalutamide
KR1020047007359A KR20050044468A (ko) 2001-11-16 2002-11-14 비칼루타미드를 포함하는 약학 제제
DE60217390T DE60217390T2 (de) 2001-11-16 2002-11-14 Bicalutamid enthaltende pharmazeutische zusammensetzung
CNA028272277A CN1615122A (zh) 2001-11-16 2002-11-14 包含比卡鲁胺的药物制剂
ARP020104386A AR037390A1 (es) 2001-11-16 2002-11-14 Formulacion farmaceutica
MXPA04004591A MXPA04004591A (es) 2001-11-16 2002-11-14 Formulacion farmaceutica que contiene bicalutamida.
AU2002343024A AU2002343024A1 (en) 2001-11-16 2002-11-14 Pharmaceutical formulation comprising bicalutamide
JP2003545287A JP2005514355A (ja) 2001-11-16 2002-11-14 ビカルタミドを含んでなる医薬製剤
BR0214135-3A BR0214135A (pt) 2001-11-16 2002-11-14 Produto farmacêutico, dose farmacêutica, usos de um anti-estrogênio e de um inibidor da aromatase e 4'-ciano-alfa', alfa, alfa'-trifluoro-3-(4-fluorofenilsulfonil)-2-hidróxi-2- metilpropiono-m-toluidida ou um sal ou solvato farmaceuticamente aceitáveis destes, e, método para tratar de câncer da próstata e/ou reduzir o risco de câncer da próstata em um paciente
ZA200403689A ZA200403689B (en) 2001-11-16 2004-05-13 Pharmaceutical formulation comprising bicalutamide
NO20042502A NO20042502L (no) 2001-11-16 2004-06-15 Farmasoytisk formulering omfattende bicalutamid

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0103839A SE0103839D0 (sv) 2001-11-16 2001-11-16 Pharmaceutical formulation & product

Publications (1)

Publication Number Publication Date
SE0103839D0 true SE0103839D0 (sv) 2001-11-16

Family

ID=20286023

Family Applications (1)

Application Number Title Priority Date Filing Date
SE0103839A SE0103839D0 (sv) 2001-11-16 2001-11-16 Pharmaceutical formulation & product

Country Status (20)

Country Link
US (1) US20050038111A1 (de)
EP (1) EP1448168B1 (de)
JP (1) JP2005514355A (de)
KR (1) KR20050044468A (de)
CN (1) CN1615122A (de)
AR (1) AR037390A1 (de)
AT (1) ATE350016T1 (de)
AU (1) AU2002343024A1 (de)
BR (1) BR0214135A (de)
CA (1) CA2466986A1 (de)
DE (1) DE60217390T2 (de)
ES (1) ES2278063T3 (de)
IL (1) IL161902A0 (de)
MX (1) MXPA04004591A (de)
NO (1) NO20042502L (de)
SE (1) SE0103839D0 (de)
TW (1) TW200406200A (de)
UY (1) UY27539A1 (de)
WO (1) WO2003043606A1 (de)
ZA (1) ZA200403689B (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ20032225A3 (cs) * 2001-02-27 2003-11-12 Astrazeneca Ab Farmaceutická formulace
US7524866B2 (en) 2001-11-29 2009-04-28 Gtx, Inc. Prevention and treatment of androgen—deprivation induced osteoporosis
US7332525B2 (en) * 2003-01-17 2008-02-19 Castle Erik P Method of treatment of prostate cancer and composition for treatment thereof
US7226622B2 (en) 2003-09-18 2007-06-05 Boston Scientific Scimed, Inc. Chemoablation of tissue using biodegradable, solid salt dosage forms
CA2554025A1 (en) * 2004-01-28 2005-08-11 Androscience Corporation Enhancement of anti-androgenic activity by a combination of inhibitors targeting different steps of a steroid-dependent gene activation pathway and uses thereof
JP2008511607A (ja) * 2004-08-31 2008-04-17 ファイザー・プロダクツ・インク 低溶解性薬物および重合体を含む医薬投与剤形
GB0424339D0 (en) * 2004-11-03 2004-12-08 Astrazeneca Ab Combination therapy
WO2006090129A2 (en) * 2005-02-23 2006-08-31 Astrazeneca Ab Bicalutamide for delivering increasing steady state plasma levels
KR20070114343A (ko) * 2005-03-29 2007-12-03 유에스브이 리미티드 비칼루타미드의 제조 방법
US20090291134A1 (en) * 2006-11-21 2009-11-26 Jina Pharmaceuticals, Inc. Endoxifen methods and compositions in the treatment of psychiatric and neurodegenerative diseases
PL2252893T3 (pl) * 2008-02-21 2014-03-31 Iris Int Inc Sposób wczesnego określenia nawrotu po leczeniu nowotworu gruczołu krokowego
AU2009292615B2 (en) * 2008-09-17 2015-12-03 Mylan Inc. Granulates, process for preparing them and pharmaceutical products containing them
TWI673051B (zh) 2012-09-11 2019-10-01 美商梅維森前列腺療法有限責任公司 恩雜魯它脈（ｅｎｚａｌｕｔａｍｉｄｅ）之調和物
WO2016198983A1 (en) 2015-06-09 2016-12-15 Bend Research Inc. Formulations to achieve rapid dissolution of drug from spray-dried dispersions in capsules
CN107049972A (zh) * 2017-03-17 2017-08-18 万特制药(海南)有限公司 一种含有来曲唑固体分散体的分散片及其制备工艺

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3121152A1 (de) * 1981-05-22 1982-12-09 Schering Ag, 1000 Berlin Und 4619 Bergkamen "verwendung der kombination eines aromatase-hemmers mit einem antiandrogen zur prophylaxe und therapie der prostatahyperplasie"
US4895715A (en) * 1988-04-14 1990-01-23 Schering Corporation Method of treating gynecomastia
CA2181358A1 (en) * 1994-01-21 1995-07-27 Nancy M. Gray Methods and compositions for treating androgen-dependent diseases using optically pure r-(-)-casodex
GB9707800D0 (en) * 1996-05-06 1997-06-04 Zeneca Ltd Chemical compounds
US6139875A (en) * 1998-09-29 2000-10-31 Eastman Chemical Company Aqueous enteric coating composition and low gastric permeability enteric coating

Also Published As

Publication number Publication date
CA2466986A1 (en) 2003-05-30
AR037390A1 (es) 2004-11-10
BR0214135A (pt) 2004-10-13
JP2005514355A (ja) 2005-05-19
EP1448168B1 (de) 2007-01-03
MXPA04004591A (es) 2004-08-13
US20050038111A1 (en) 2005-02-17
CN1615122A (zh) 2005-05-11
UY27539A1 (es) 2003-07-31
KR20050044468A (ko) 2005-05-12
ZA200403689B (en) 2006-06-28
DE60217390T2 (de) 2007-11-15
DE60217390D1 (de) 2007-02-15
WO2003043606A1 (en) 2003-05-30
ATE350016T1 (de) 2007-01-15
NO20042502L (no) 2004-08-09
ES2278063T3 (es) 2007-08-01
IL161902A0 (en) 2005-11-20
AU2002343024A1 (en) 2003-06-10
TW200406200A (en) 2004-05-01
EP1448168A1 (de) 2004-08-25

Similar Documents

Publication Publication Date Title
MXPA04004591A (es) Formulacion farmaceutica que contiene bicalutamida.
IS6970A (is) Lyfjablanda á föstu formi sem felur í sér 4-sýanó-tríflúor-3-(4-flúorfenýlsúlfonýl)-2-hýdroxý-2-metýlprópíón-m-tólúidíð og PVP
DE602004017194D1 (de) Pyridylpyrrol-derivate als wirksame kinase-hemmer
CR8352A (es) Formulaciones farmaceuticas, procedimientos y pautas de dosificacion para el tratamiento y prevencion de sindromes coronarios agudos
BR0110877A (pt) Métodos de tratamento de câncer primário, de aumento da dosagem de um inibidor de topoisomerase, de redução ou prevenção de um efeito adverso associado com quimioterapia e com terapia de radiação, de aumento da eficácia terapêutica de um inibidor de topoisomerase, e de proteção de um paciente canceroso dos efeitos adversos associados com a administração de uma droga anti-câncer, composição farmacêutica, forma de dosagem, e, kit para uso no tratamento de câncer
MXPA05012573A (es) Derivados de pirazolo-quinazolina, procedimiento para su preparacion y su uso como inhibidores de cinasa.
MXPA06000302A (es) Derivados de pirazolil-indol activos como inhibidores de cinasa, procedimientos para su preparacion y composiciones farmaceuticas que los comprenden.
UY27186A1 (es) Formulación farmacéutica
ATE396986T1 (de) Pyrimidylpyrrolderivate, die als kinaseinhibitoren wirken
UA85359C2 (ru) Таблетка, содержащая гранулированный материал с kmd-3213
SE0103424D0 (sv) Pharmaceutical formulation
ATE341319T1 (de) Esmolol-enthaltende zubereitungen
JP2022523094A5 (de)
SE0103838D0 (sv) Pharmaceutical formulation & product
MXPA06007510A (es) Composiciones de farmaco y formas de dosis novedosas de topiramato.
JP2022543679A5 (de)
SE9901572D0 (sv) New compounds
SE0102887D0 (sv) New formulation
BRPI0416316A (pt) combinação de um inibidor da farnesil transferase com um agente anti-hormonal para o tratamento de cáncer de mama
SE0102886D0 (sv) New formulation
RU2003133136A (ru) Новое применение производных арилэтенсульфонамида
SE0102888D0 (sv) New formulation
JP2017514834A5 (de)
UA144734U (uk) Спосіб лікування вірусних інфекційних захворювань
TH68406A (th) การให้ยาเดือนละครั้งสำหรับรักษาการติดเชื้อสเตรปโทคอคคัส นิวโมนิเอ